Vergleich

Adezmapimod (SB203580) Europäischer Partner

ArtNr S1076-25
Hersteller Selleckchem
CAS-Nr. 152121-47-6
Menge 25 mg
Quantity options 100 mg 1 g 10 g 1000 mg 10 mM/1 mL 200 mg 25 mg 50 mg 5 g
Kategorie
Typ Inhibitors
Specific against other
Smiles CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias RWJ 64809,PB 203580
Similar products SB
Lieferbar
Storage Conditions
3 years -20°C (in the dark) powder
Molecular Weight
377, 43
Administration
Orally administered
Animal Models
Systemic lupus erythematosus (SLE) are established in female MRL/lpr mice and female C57BL/6 mice
Cell lines
CT6 cell , BA/F3 F7 cell
Concentrations
0–30 uM
Dosages
0.4 ml/day
Formulation
Dissolved in drinking water (250 uM)
IC50
0.3–0.5 uM, 0.3–0.5 uM, 0.3–0.5 uM, 0.3–0.5 uM, 0.3–0.5 uM, 0.3–0.5 uM
In vitro
SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 um. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 um. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 um range. [1] SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 uM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 uM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-kappaB transcriptional activity. [2] SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. [3]
In vivo
SB203580 protects pig myocardium against ischemic injury in an in vivo model. [4]SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE). [5]
Incubation Time
1 hour
Kinase Assay
Cellular receptor kinase phosphorylation assay, 4 ug of sheep anti-PKBalpha is immobilized on 25 uL of protein G-Sepharose overnight (or 1.5 hours) and washed in Buffer A (50 mm Tris, pH 7.5, 1 mm EDTA, 1 mm EGTA, 0.5 mm Na3VO4, 0.1% beta-mercaptoethanol, 1% Triton X-100, 50 mm sodium fluoride, 5 mm sodium pyrophosphate, 0.1 mm phenylmethylsulfonyl fluoride, 1 ug/mL aprotinin, pepstatin, leupeptin, and 1 um microcystin). The immobilized anti-PKB is then incubated with 0.5 ml of lysate (from 5 x 106 cells) for 1.5 hours and washed three times in 0.5 mL of Buffer A supplemented with 0.5 m NaCl, two times in 0.5 mL of Buffer B (50 mm Tris-HCl, pH 7.5, 0.03% (w/v) Brij-35, 0.1 mm EGTA, and 0.1% beta-mercaptoethanol), and twice with 100 ul of assay dilution buffer, 5x assay dilution buffer is 100 mm MOPS, pH 7.2, 125 mm beta-glycerophosphate, 25 mm EGTA, 5 mm sodium orthovanadate, 5 mm DTT. To the PKB enzyme immune complex is added 10 uL of assay dilution buffer, 40 um protein kinase A inhibitor peptide, 100 um PKB-specific substrate peptide, and 10 uCi of [gamma-32P]ATP, all made up in assay dilution buffer. The reaction is incubated for 20 minutes at room temperature with shaking, then samples are pulse spun, and 40 uL of reaction volume are removed into another tube to which is added 20 uL of 40% trichloroacetic acid to stop the reaction. This is mixed and incubated for 5 minutes at room temperature, and 40 uL is transferred onto P81 phosphocellulose paper and allowed to bind for 30 seconds. The P81 piece is washed three times in 0.75% phosphoric acid then in acetone at room temperature., gamma-32P incorporation is then measured by scintillation counting.
Method
CT6 cell and BA/F3 F7 cell are rested by washing three times in RPMI and culturing overnight in RPMI, 5% fetal calf serum in the absence of growth factor, antibiotics, or beta-mercaptoethanol supplements. 2–5, 106 rested CT6 cells are resuspended in 2 mL of RPMI, 5% fetal calf serum and preincubated with SB203580 or vehicle control as indicated in figure legends. Cells are then stimulated with 20 ng/ml recombinant human IL-2 for 5 minutes at 37 C and pelleted in a minifuge for 30 seconds, medium is aspirated, and the pellet is lysed in the appropriate buffer. BA/F3 cells stably expressing deletion mutants of IL-2 receptor beta chain are maintained in glutamine containing RPMI further supplemented with 5% fetal calf serum and 0.2 ug/mL G418. The cells are then washed extensively, rested overnight, and washed again before activating with IL-2, such cell preparations are >90% T cells. Cellular proliferation assays are performed by measurement of [3H]thymidine incorporation.
Solubility (25C)
DMSO 76 mg/mL, Water <1 mg/mL, Ethanol 5 mg/mL
Information
Adezmapimod (SB203580, RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.
Chemical Name
4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine
Features
First reported p38 inhibitor

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 25 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?